Citadel Advisors
DAWN

Citadel Advisors’s Day One Biopharmaceuticals DAWN Stock Holding History

Citadel Advisors’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.61M Buy
261,700
+73,800
+39% +$1.04M ﹤0.01% 4160
2025
Q4 		$1.75M Buy
+187,900
New +$1.57M ﹤0.01% 6190
2025
Q3 		– Sell
-19,600
Closed -$127K – 12960
2025
Q2 		$127K Buy
19,600
+7,800
+66% +$53.7K ﹤0.01% 11107
2025
Q1 		$93.6K Sell
11,800
-6,600
-36% -$71.1K ﹤0.01% 11566
2024
Q4 		$233K Buy
18,400
+8,800
+92% +$122K ﹤0.01% 10162
2024
Q3 		$134K Sell
9,600
-16,500
-63% -$235K ﹤0.01% 10705
2024
Q2 		$360K Buy
26,100
+10,800
+71% +$158K ﹤0.01% 8755
2024
Q1 		$253K Sell
15,300
-3,000
-16% -$44.9K ﹤0.01% 9839
2023
Q4 		$267K Buy
18,300
+1,400
+8% +$17K ﹤0.01% 9388
2023
Q3 		$207K Sell
16,900
-19,100
-53% -$249K ﹤0.01% 9837
2023
Q2 		$430K Sell
36,000
-16,400
-31% -$214K ﹤0.01% 8270
2023
Q1 		$701K Buy
52,400
+25,800
+97% +$504K ﹤0.01% 7567
2022
Q4 		$572K Buy
+26,600
New +$546K ﹤0.01% 7965
2022
Q3 		– Sell
-57,600
Closed -$1.03M – 12782
2022
Q2 		$1.03M Buy
+57,600
New +$595K ﹤0.01% 6950

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Citadel Advisors's DAWN Position: Q1 2026 in Review

Citadel Advisors sold out of Day One Biopharmaceuticals (DAWN) in Q1 2026, closing a stake of 1,359,613 shares — an estimated $19.2M sold.

Citadel Advisors first reported a position in DAWN in Q1 2022 and held it in 16 quarters. The position peaked at $12.7M in Q4 2025. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Citadel Advisors reported no remaining Day One Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 1,359,613 Day One Biopharmaceuticals shares in Q1 2026, an estimated $19.2M.
  • Citadel Advisors first reported a position in Day One Biopharmaceuticals in Q1 2022 and held it in 16 quarters.
  • Citadel Advisors's Day One Biopharmaceuticals position peaked at $12.7M in Q4 2025.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.